BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical firm centered on creating subsequent technology therapeutics to advance requirements of care in areas of serious unmet medical want, has been invited to take part in a hearth chat as a part of the Piper Sandler 32nd Annual Digital Healthcare Convention, being held December 1-3, 2020. The Firm can even host investor conferences in the course of the convention.
The pre-recorded fireplace chat can be accessible on the IR Calendar web page of the Traders part of the Firm’s web site (www.matinasbiopharma.com) starting November 23, 2020. A webcast replay can be accessible for 90 days following the occasion.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical firm centered on creating subsequent technology therapeutics to advance requirements of look after sufferers in areas of serious unmet medical want. Firm management has a deep historical past and information of drug growth and is supported by a world-class staff of scientific advisors.
MAT9001, the Firm’s lead product candidate for the remedy of cardiovascular and metabolic circumstances, is a prescription-only omega-Three fatty acid-based composition, comprised primarily of EPA and DPA, below growth for hypertriglyceridemia. MAT9001 is at the moment in a second head-to-head comparative research towards Vascepa® (ENHANCE-IT), with topline knowledge anticipated within the first quarter of 2021.
As well as, Matinas is creating a portfolio of merchandise primarily based upon its proprietary lipid nano-crystal (LNC) drug supply platform, which may clear up complicated challenges regarding the protected and efficient supply of potent medicines, making them extra focused, much less poisonous and orally bioavailable.
MAT2203, the Firm’s lead product candidate using its LNC platform, is an oral, encochleated formulation of the well-known, however extremely poisonous, antifungal medication amphotericin B, to deal with critical invasive fungal infections. MAT2203 is at the moment in a Part 2 open-label, sequential cohort research (EnACT) in HIV-infected sufferers with cryptococcal meningitis. EnACT is ready to start enrolling sufferers in its second cohort, with the subsequent DSMB analysis of security and efficacy knowledge anticipated to happen in the midst of 2021.
Ahead Wanting Statements
This launch incorporates “forward-looking statements” throughout the which means of the Personal Securities Litigation Reform Act of 1995, together with these regarding the Firm’s anticipated capital and liquidity wants, strategic focus and the long run growth of its product candidates, together with MAT2203 and MAT2501, the anticipated timing of regulatory submissions, the anticipated timing of medical research, the anticipated timing of regulatory interactions, the Firm’s capacity to establish and pursue growth and partnership alternatives for its merchandise or platform supply expertise on favorable phrases, if in any respect, and the power to acquire required regulatory approval and different statements which might be predictive in nature, that depend on or seek advice from future occasions or circumstances. All statements apart from statements of historic truth are statements that might be forward-looking statements. Ahead-looking statements embrace phrases corresponding to “expects,” “anticipates,” “intends,” “plans,” “might,” “believes,” “estimates” and related expressions. These statements contain recognized and unknown dangers, uncertainties and different components which may trigger precise outcomes to be materially totally different from any future outcomes expressed or implied by the forward-looking statements. Ahead-looking statements are topic to various dangers and uncertainties, together with, however not restricted to, our capacity to acquire extra capital to fulfill our liquidity wants on acceptable phrases, or in any respect, together with the extra capital which can be obligatory to finish the medical trials of our product candidates; our capacity to efficiently full analysis and additional growth and commercialization of our product candidates; the uncertainties inherent in medical testing; the timing, price and uncertainty of acquiring regulatory approvals; our capacity to guard the Firm’s mental property; the lack of any govt officers or key personnel or consultants; competitors; modifications within the regulatory panorama or the imposition of rules that have an effect on the Firm’s merchandise; and the opposite components listed below “Threat Components” in our filings with the SEC, together with Varieties 10-Ok, 10-Q and 8-Ok. Traders are cautioned to not place undue reliance on such forward-looking statements, which communicate solely as of the date of this launch. Besides as may be required by legislation, the Firm doesn’t undertake any obligation to launch publicly any revisions to such forward-looking statements to replicate occasions or circumstances after the date hereof or to replicate the incidence of unanticipated occasions. Matinas BioPharma’s product candidates are all in a growth stage and usually are not accessible on the market or use.
Investor and Media Contacts
Peter Vozzo
Westwicke
443-213-0505
peter.vozzo@westwicke.com
Ian Cooney
Director – Investor Relations & Company Improvement
Matinas Biopharma, Inc.
(415) 722-4563
icooney@matinasbiopharma.com
